Skip to main content
Premium Trial:

Request an Annual Quote

Tm Biosciences Pockets $9M Through Convertible Note Sale

NEW YORK, Nov. 23 (GenomeWeb News) - Toronto-based Tm Biosciences has pocketed $9 million through the sale of a convertible note to Laurus Master Fund, the company said today.


Laurus has also been issued a warrant to buy approximately 740,000 common shares in Tm at a price of $2.61. The warrant expires in 2010.


Jim Pelot, TM's chief financial officer, said the transaction allows the company to "retire its existing debt ensuring that [it has] suitable working capital" to grow its business.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.